Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Korea ETF (EWY) vs Moderna, Inc. (MRNA) Price & Performance

iShares MSCI South Korea ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI South Korea ETF vs Moderna, Inc. — how do they compare? iShares MSCI South Korea ETF trades at $175.8, while Moderna, Inc. trades at $60.51 (market cap $24.18B). Which is the better fit depends on your goals.

EWYMRNA
Sector
Broad Market / FactorHealth
52-Week High
$219.20$81.80
52-Week Low
$71.22$22.36
Market Cap
$24.18B
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Korea ETF

EWY trades at $175.21, up 7.41% over the past 24 hours, showing strong momentum amid volatile South Korean market conditions. The ETF exhibits mixed technical signals with bullish moving averages but neutral oscillators, while support and resistance levels indicate potential consolidation between $166 and $172. Recent news highlights significant volatility in South Korean equities driven by AI and semiconductor sector turbulence, with foreign investors rotating capital away from Asian markets.

The outlook remains cautious as EWY faces headwinds from concentrated exposure to South Korea's volatile semiconductor sector, though government support initiatives and Goldman Sachs' bullish 90% upside projection offer potential catalysts. Key risks include continued foreign capital outflows, leveraged ETF speculation concerns, and dependence on AI-driven market swings that have caused recent sharp declines in major holdings like Samsung and SK Hynix.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA